Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San ...

Researchers conducted a systematic review to assess the risk of bias and applicability of prediction models for fear of recurrence in patients with cancer.

Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...

Tranexamic acid significantly enhances hemostasis, achieving success rates between 83.1% and 95.0% when applied both ...

Background:The COVID-19 pandemic affected the epidemiology of respiratory syncytial virus (RSV). We sought to describe ...